https://www.selleckchem.com/MEK.html
1 criteria. A prominent control in the metastatic lesions were also observed in 18F-FDG PET-CT scan. Evidence for systemic management of metastatic CBTs is mainly based on studies of PGLs and pheochromocytoma. According to our review on metastatic CBT cases treated with systemic therapy from 1981 to 2018, chemotherapy, especially the CVD regimen, was a common reported management. In SDHB mutated patients, sunitinib and temozolomide could also be considered. Evidence for systemic management of metastatic CBTs is mainly based on studies of PGLs and ph
Like
Comment
Share
